Genitourinary cancers

Why we focus on genitourinary cancers

Cancers of the prostate, testis, penis, kidney and bladder account for over 16% of all new cases of cancer and collectively are slightly more common than breast cancer. Prostate cancer is the most common cancer in men and testicular cancer the most common tumour in young men between the ages of 15 and 35 years. Despite high five year survival rates for testicular (97%) and prostate (80%) cancer, collectively these malignancies account for almost 12% of cancer deaths. Therefore, it remains important to improve our knowledge of the biology of these diseases, and so identify targets for new and novel therapies, particularly for chemoresistance.

What we do
  • Establish and maintain a male urogenital cancer tissue bank
  • Identify critical genes in testicular tumour cisplatin‑resistance using genome-wide analysis
  • Identify key biomarkers in penile cancer and investigate the  role of HPV in its development
  • Focus on resistance mechanisms to targeted therapies used to treat renal cancer
  • Investigate (in vitro and in vivo) the therapeutic potential and resistance mechanisms of HER 1-4, FGF-2 and Src-targeted therapy in bladder and renal cancer, and the role of ASS1
  • Run clinical trials for optimised chemotherapy of testicular tumours
  • Run translational clinical trials investigating novel targeted and immune therapies
  • Run clinical trials for new treatments for bladder and renal cancer.
Major Funders
  • Orchid
  • Association for International Cancer Research
  • Cancer Research UK
  • GlaxoSmithKline
  • Medical Research Council
  • Novartis Pharmaceuticals UK Ltd
Key Publications